Clinical and estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2 status correlation study in breast cancer patients: An experience from a tertiary care center

Abstract

Background: Breast cancer is usually a systemic disease with outcomes dependent on various factors. We present here our departmental retrospective data of 74 breast cancer patients treated between January 2016 and October 2017, with a focus on various prognostic and predictive factors. Materials and Methods: Patients' details were retrieved from departmental case records regarding age, menopausal status, tumor size (T), axillary lymph node status (N), grade, and estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (Her2) status. Using SPSS software version 20.0, cross-tabulation, the Chi-square test, and Spearman correlation were applied where appropriate. Results: The median age of patients was 48.75 ± 11.08 years with more patients in premenopausal age (54.1%). Stage III was the most common presentation (66.2%). In addition, Grade 3 in tumor was most common (51.4%). ER(+), PR(+), and Her2(+) cases were 58.1%, 52.7%, and 28.4%, respectively. Nearly 29.7% of patients were triple negative. Grade of the tumor correlated significantly with tumor size and lymph node staging (P = 0.002). In addition, ER and PR expression was correlated with each other (P = 0.000). Conclusions: Advanced stage, higher tumor grade, and high prevalence of Triple-negative breast cancer in our patients are poor prognostic and predictive factors. Higher tumor grade is correlated with increased T and N staging, and tumor ER and PR expressions were correlated with each other.

Keywords

• breast cancer
• clinical
• estrogen receptor
• human epidermal growth factor receptor-2
• progesterone receptor